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ABSTRACT 
 
Objective: This study aimed to investigate the relationship between 
compulsivity versus impulsivity and structural MRI abnormalities in opioid 
dependence. 
Method: We recruited 146 participants: i) patients with a history of opioid 
dependence due to chronic heroin use (n=24), ii) heroin users stabilised on 
methadone maintenance treatment (n=48), iii) abstinent participants with a 
history of opioid dependence due to heroin use (n=24) and iv) healthy controls  
(n=50). Compulsivity was measured using Intra/Extra-Dimensional (IED) Task 
and impulsivity was measured using the Cambridge Gambling Task (CGT). 
Structural Magnetic Resonance Imaging (MRI) data were also obtained. 
Results: As hypothesised, compulsivity was negatively associated with 
impulsivity (p<0.02). Testing for the neural substrates of compulsivity versus  
impulsivity, we found a higher compulsivity/impulsivity ratio associated with 
significantly decreased white matter adjacent to the nucleus accumbens, bed 
nucleus of stria terminalis and rostral cingulate in the abstinent group, 
compared to the other opioid dependent groups. In addition, self-reported 
duration of opioid exposure correlated negatively with bilateral globus pallidus 
grey matter reductions. 
Conclusion: Our findings are consistent with Volkow & Koob’s addiction 
models and underline the important role of compulsivity versus impulsivity in 
opioid dependence. Our results have implications for the treatment of opioid 
dependence supporting the assertion of different behavioural and biological 
phenotypes in the opioid dependence and abstinence syndromes. 
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Significant Outcomes:  
 Both heroin users and short-term abstinent participants made 
significantly more errors on the compulsivity (IED) task than healthy 
controls. 
 Brain structure abnormalities associated with compulsivity versus  
impulsivity were identified. 
 Compulsivity was negatively associated with impulsivity and the ratio of 
compulsivity/impulsivity was inversely related to nucleus accumbens, 
and bed nucleus of stria terminalis white matter integrity. 
 
 
Limitations 
 We cannot address causal effects due to the cross-sectional design of 
the current study. 
 The findings may not be generalised to female populations as we 
recruited only treatment-seeking male individuals. 
 
 
 
 
Abbreviations: 
ABS: Abstinent group 
ANOVA: Analysis of Variance 
ANCOVA: Analysis of Covariance 
BNST: Bed Nucleus of Stria Terminalis 
CGT: Cambridge Gambling Task 
IED: Intra/Extra-dimensional,  
H: Heroin group  
HC: Healthy Control group 
MMT: Methadone Maintenance Treatment group 
MRI: Magnetic Resonance Imaging 
SPM: Statistical Parametric Mapping  
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Introduction 
  
Volkow & Koob (2016) described drug addiction as a disorder that progresses 
from impulsivity to compulsivity characterised by maladaptive behaviour to 
obtain and consume more drugs at the expense of health and social 
interactions [1]. Chronic exposure to opioids occurs frequently in both 
therapeutic pain and substance misuse populations [2]. Methadone 
Maintenance Therapy (MMT) represents a dominant treatment intervention for 
a substantial number of people who become dependent on chronic illicit opioid 
use such as heroin [3,4]. From the range of studies that have examined the 
impact of methadone on neuropsychological functioning, there seems to be an 
evidence base describing impairment in methadone users in a number of 
neuropsychological domains [5]. Studies which have compared methadone 
users with abstinent ex-heroin dependent and substance free healthy controls 
have indicated that the abstinent ex-heroin dependent group performed at a 
superior level to methadone users but below the level of substance free and 
healthy controls [5]. For example Darke et al (2012) compared cognitive 
domains in 125 current opioid users, 50 abstinent and 50 healthy controls. 
They concluded that current opioid users have a poorer performance on some 
tests compared to abstinent and control groups [6]. 
This suggests that neuropsychological deficits observed in opioid users 
may be subject to at least partial recovery with total withdrawal from opioids, 
but that some permanent damage may occur. However, interpretation of these 
results must be be done with caution, as there were a number of possible 
causes of neuropsychological dysfunction in this population. These include 
the pre-drug misuse traits in people who go on to become dependendent on 
opioid drugs, traits associated with dependent individuals who achiece 
abstainence, as well as effects of the drug itself and any other illicit or 
prescribed substances, alcohol abuse, head injury, overdose, or comorbid 
psychiatric disorders. Unfortunately it is difficult to address traits without a 
longitudinal study and each possible confounding variable is common in the 
opioid dependent population. It is therefore likely that factors other than the 
direct effects of methadone account for at least some of the wide range of 
deficits observed in the clinical research literature [2,7].  
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Previously we reported that patients on MMT and others still taking 
illicit heroin exhibited heightened impulsivity [7,8]. This was supported by our 
previous meta-analysis suggesting robust impairment in cognitive impulsivity 
(risk taking) with a moderate effect size of 0.70 (p<0.01) [2]. In contrast to 
studies on impulsivity, there are far fewer studies on compulsivity [9] and none 
to our knowledge on abstinent former opioid users which include use of 
structural Magnetic Resonance Imaging (MRI). 
Robbins et al (2012) argued that impulsivity and compulsivity are 
cognitive endophenotypes with impulsivity relevant for initiating actions, 
whereas compulsivity is more linked with terminating actions [9]. In addition, 
Meunier et al (2012) and Ersche et al (2011) linked compulsivity to 
orbitofrontal cortex [10,11]. Friedman et al (2000)  compared opioid symptoms 
to Obsessive Compulsive Disorder (OCD) [12]. These authors concluded that 
the level of compulsivity and obsessionality in opioid dependence is similar to 
OCD and alcohol addiction, and rituals were inversely related to the number of 
relapses during opioid rehabilitation, being positively correlated with non-drug 
OCD symptoms.  
Previous neuroimaging studies have reported abnormal brain structure 
in opioid users [6,13] with compulsive behaviour linked to abnormalities in the 
orbitofrontal cortex and striatum [10,11]. Intra/Extra-Dimensional task (a 
neurocognitive task that measures compulsivity) conducted studies have 
confirmed a preferential role for dopamine in non-opioid-dependent-heroin-
using patients [14-17], particularly in the ventral striatum, an important part of 
the brain reward circuitry. In this context, low dopamine tone might be a 
plausible neurobiological mechanism contributing to opioid dependence [1]. 
However, previous behavioural and neuroimaging studies investigating this 
question have generated inconsistent results [18]. Changes in both 
compulsivity and impulsivity have been linked to functional changes in brain 
regions such as the extended amygdala (central nucleus of amygdala and bed 
nucleus stria terminalis) and the shell of the nucleus accumbens, both of 
which receive dense dopaminergic innervation [8]. Holander and Wong 
proposed an impulsive-compulsive diathesis model with impulsivity and 
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compulsivity at the opposite ends of a single dimension, implying a negative 
correlation between impulsivity and compulsivity measures [19]. In contrast 
Fineberg and colleagues proposed that the two constructs may be considered 
as endophenotypes representing uncorrelated factors: i.e. a characteristic 
tendency to reward-seeking behaviour (impulsivity) and an uncorrelated drive 
to avoid punishment (compulsivity) [20].  
Impulsivity and compulsivity constructs have similarities and 
differences [9,12]. To address the above issues, we aimed to identify brain 
structure abnormalities more linked to compulsivity than impulsivity, by testing  
for correlations between grey and white matter probability and the ratio of 
compulsivity/impulsivity measures.  
We predicted impairment in compulsivity in  three groups of opioid 
dependent patients when compared to the healthy control group. Second, we 
predicted the extent of these impairments would correlate with impulsivity. 
Specifically, we investigated a possible association between caudate nucleus 
and orbitofrontal cortex structure with compulsivity measures relative to 
impulsivity measures in opioid dependence. Finally, based on previous 
studies [23,24], we predicted that behavioural impairment would be 
associated with the duration of exposure to chronic opioid usage. 
 
Material and Methods  
The study was approved by the local Research Ethics Committee (REC 
Reference Number 06/S1401/32) 
  
Study 1 (Neurocognition) 
  
Study samples 
One hundred and forty-six male participants were recruited into four groups; 
opioid dependent and daily illicit chronic heroin (H) group (n=24), opioid 
dependent chronic methadone maintenance (MMT) group (n=48), formerly 
opioid dependent and currently abstinent (ABS) group (n=24) and non opioid 
dependent healthy control (HC) group (n=50). The ABS group had a history of 
chronic opioid use of more than three years and were objectively free from all 
opioids and other psychoactive substances between six and twenty weeks 
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after a period of rehabilitation. Diagnoses were made according to the Mini 
International Neuropsychiatric Interview (MINIPlus v. 5.0) [25]. Detailed drug 
histories and relevant demographic data were acquired prior to testing by  one 
of the authors (AB). At the time of testing, no participants experienced clinical 
opioid withdrawal symptoms or presented with features of intoxication. The 
Clinical Opiate Withdrawal scale (COWS) was used to quantify the level of 
opioid withdrawal [26]. Current and premorbid intelligence was estimated 
using the Wechsler Abbreviated Scale of Intelligence (WASI) and National 
Adult Reading Test (NART) [27] respectively. The Fagerström test for Nicotine 
Dependence [28] was used to quantify nicotine dependence. All individuals 
were right handed. Exclusion criteria for all groups were: past or current 
histories of psychotic disorder, post-traumatic stress disorder, neurological 
and neurodevelopmental disorders, head injury, confirmed history of non-fatal 
overdose episodes requiring hospitalisation, diagnoses of antisocial and 
borderline personality disorder and presence of co-occurring benzodiazepine, 
stimulant and/or alcohol dependence. By the time individuals consented into 
this study none were subsequently excluded and they completed all tests.The 
screening and diagnostic tests used in this study are reported in 
Supplementary Table 1. 
 
Compulsivity and Impulsivity 
Each participant was assessed by an experienced and trained senior clinical 
nurse using the Intra-Extra Dimensional (IED) set shifting task and Cambridge 
Gambling Task (CGT) from the Cambridge Neuropsychological Test 
Automated Battery (CANTAB) (www.cambridgecognition.com), which 
assessed compulsivity and impulsivity respectively [7, 20-23]. In a recent 
review, Fineberg and colleagues proposed that the CGT measures ‘cognitive 
impulsivity’ and quality of decision-making and the IED measures compulsivity 
and ‘cognitive inflexibility’ [20].  Consistent with the literature, we used the 
following outcome measures as indices of cognitive impulsivity derived from 
the CGT: quality of decision-making, risk taking, deliberation time, delay 
aversion and risk adjustment [7,8,20]. Compulsivity measures include pre-ED 
errors, EDS errors and total errors. Total errors and total trials (adjusted) 
variables report the total number of errors with an adjustment for the stages 
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not attempted due to previous failure. We chose these variables because our 
previous meta-analysis highlighted abnormalities in these measures [7]. All 
participants were tested with the same neuropsychological test battery in a 
fixed order.  
 
Statistical analysis  
Data were analysed using ANOVA and ANCOVA. Nonparametric tests were 
used when data did not meet the assumptions of normality and homogeneity 
of variance. ANOVA was used to test for group differences. To control for 
family-wise error we used post-hoc Bonferroni-corrected pairwise 
comparisons. After correction, results with p<0.05 were considered significant. 
ANCOVA was used to test for removing the effect of covariate factors: pre-
morbid IQ and age. Effect sizes were calculated using Cohen’s d statistics. 
Analyses were conducted using SPSS v20 (SPSS IBM, USA). 
 
 
Study 2 (Neuroimaging) 
  
Participants 
A representative subset of the participants from Study 1 took part in Study 2. 
From the overall group we tested a total of seventy-one individuals: MMT 
group (n=33), ABS group (n=15) and HC group (n=23).  
 
Scanning 
T1 weighted images were acquired with a voxel size 0.8x0.8x1.0 mm with 
whole brain coverage, TR 1.9 sec and TE 2.64 ms using a Siemens 3T Trio. 
An experienced Consultant Radiologist reported any incidental findings. 
 
Image analyses 
Voxel based morphometry (VBM) was done using SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/) [29]. For pre-processing, T1 weighted 
images for each participant were segmented into grey and white matter 
probability maps, spatially normalised with modulation to preserve the total 
amount of matter and smoothed with an 8mm Gaussian kernel [30]. T-tests 
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were used to test the null hypothesis of no difference between patient groups 
and controls.  
 
We tested for significant reductions in grey and white matter in methadone 
and abstinent groups relative to controls.  Correlation analyses were used to 
test the null hypotheses of no relation between white matter and grey matter 
measures with IED behavioural measures, ratio of IED/CGT behavioural 
measures (reflecting the relative effect of compulsivity to impulsivity), and self-
report duration of opioid exposure as years. The threshold of significance was 
defined as p<0.05 at a whole brain corrected level using a popular Monte 
Carlo technique [31] (http://www2.bc.edu/~slotnics/scripts.htm). Brain regions 
were identified by converting Montreal Neurological Institute coordinates into 
Talairach coordinates using the Yale conversion calculation 
(http://bioimagesuite.yale.edu/mni2tal/index.aspx) and inspection of the 
Talairach Atlas [32].  
 
Results 
Demographics 
There were no significant differences between patient groups with respect to 
clinical characteristics such as age of first heroin use, years of opioid use, 
methadone dose and severity of nicotine dependence. The mean age for the 
H group was 26.3 years for the MMT group was 30.2 years for the ABS group 
was 36.6 years and for the healthy control (HC) group 28 years. The ABS 
group was on average significantly older than the HC group in the first study. 
However, in the second study the four groups were well matched with respect 
to handedness, gender, nicotine dependence and age. The pre morbid IQ 
scores were significantly different in the ABS groups when compared with the 
HC group. Table 1 summarises the characteristics for the three opioid 
dependent groups and HC group.  
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Study 1: Behavioral effects of heroin, methadone and abstinence on 
compulsivity and impulsivity 
 
There was no significant effect of group on EDS error, [F = (3,126) = 1.7, 
p=0.2] with the ABS group making more errors than the HC goup [t = 2.5, 
p=0.045]. For total errors there was a significant effect of group [F = (3,140) = 
2.5, p=0.05], with the ABS [t = 3.1, p<0.001] and H [t = 1.3, p<0.001] groups 
making more errors than the HC group. There was a significant effect of group 
on total error adjusted [F = (3,145) = 3.2, p=0.026] with the ABS and H groups 
making more errors than the HC group [t = 3, p=0.009], [t=2.7, p=0.008]. For 
stages completed there was a significant effect of group [F = (3,145) = 2.99, 
p=0.033] with the HC group completing more stages than the ABS [t=3, 
p=0.01] and the H groups [t=-2.4, p=0.02]. There was a significant effect of 
group [F = (3, 121) = 2.8, p=0.043] with the ABS group [t=3.2, p=0.006] and 
the H group [t=2.8, p=0.007] adjusting for more trials than the HC group. 
There was a significant effect of group on pre-ED errors [F = (3,126) = 2.6, 
p=0.05] with the H group making more errors than the HC group [t=3.1, 
p=0.003]. There was no significant effect of group on completed stage errors 
[F = (3, 145) = 0.4, p=0.7], completed stage trials [F = (3, 118) = 0.4, p=0.8], 
total trails [F = (3, 99) = 0.4, p=0.8] and completed stages errors [F = (3, 145) 
= 0.3, p=0.8]. In summary, the ABS and H groups made more errors in the 
IED task than the HC group as shown in Figure 1. Table 2 summarises the 
IED task findings. The CGT findings are reported in the Supplementary 
Table 2. 
 
Correlations with compulsivity / impulsivity ratio 
A significant negative correlation between compulsivity and impulsivity 
measures [beta= -0.019, t= -2.3, p=0.02] was found across all opioid 
dependent groups. In the patient group alone we found that greater 
impairment in compulsivity total error (IED) was negatively associated with 
increased risk adjustment (CGT) [beta= -0.24, t= -2.28, p=0.03]. This 
association was also observed between the quality of decision-making (CGT) 
and pre-ED errors [beta= -0.25, t= -2.3, p=0.03]. A parallel analysis was 
performed only with the H Group and a significant effect found [beta= -0.043, 
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t= -3.4, p=0.001], also for pre-ED errors and quality of decision making 
showing that cognitive inflexibility and impulsivity were negatively correlated in 
opioid dependent participants. In addition, we found a significant association 
between self-report years of opioid misuse and compulsivity (EDS error) 
[beta= -0.37, t= -2.05, p=0.05]) and impulsivity (quality of decision making) 
[beta= 0.5, t= 3.2, p=0.004] and overall proportion of bet in the CGT [beta= 
0.38, t= 2.19, p=0.04]) (Figure 1). 
 
Study 2: Correlations with brain structure and compulsivity/impulsivity 
ratio and opioid exposure 
Figure 2 shows that a greater compulsivity/impulsivity ratio was associated in 
the ABS group with significantly decreased white matter in the nucleus 
accumbens (0, 16 -12), in the bed nucleus of stria terminalis (10, 2, -12) and 
in the rostral cingulate (6, 38, 6). In the MMT group we found that 
compulsivity/impulsivity ratio correlated negatively with amygdala (-32, -8, -
10), striatum (-2, 0, 0) and orbitofrontal cortex (2, 54, -2) white and grey matter 
values. With opioid exposure we found a negative correlation with bilateral 
globus pallidus grey matter (14, 0, -2; -16, -4, 0). 
 
Correlations with brain structure and compulsivity measures 
Increased total error adjusted correlated negatively with subgenual cingulate 
cortex (-14, 24, -12), anterior cingulate cortex (-20, 2, 34), dorsolateral 
prefrontal cortex (42, 30, 12), and ventral tegmental area (-4, -18, -6) grey 
matter. More total errors on the IED task was associated with decreased grey 
matter probability in the ventral tegmental area (-4, -20, -4), medio-prefrontal 
cortex (-12, 48, 0) and periaqueductal grey (-10, -36, -18). Increased pre-ED 
errors were associated with significantly decreased white matter in the 
anterior cingulate cortex: (-2, 8, 40), bilateral insula (44, 6, -14; -42, 4, -10) 
and nucleus accumens septi area (0, 12, 2). Increased EDS errors in the ABS 
group correlated negatively with orbitofrontal cortex (34, 58, -8), prefrontal 
cortex (20, 66, 12) white matter probability.  
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Discussion 
On the basis of Volkow & Koob’s concept of addiction, it has been proposed 
that impulsivity dominates in the early stages of addiction, whereas 
compulsivity  dominates in the later stages [4]. The present study therefore 
investigated whether compulsivity and impulsivity reflected opposite ends of a 
single dimension in opioid dependent subjects using IED and CGT 
behavioural measures and structural MRI. 
Both H and ABS groups were impaired in compulsivity measures as 
previously reported for H users [23]. As hypothesised, we also found that 
increased compulsivity correlated with decreased impulsivity. Compared to 
the HC group, the H and ABS groups made substantially more errors on the 
IED task. In the present study compulsivity and impulsivity performance was 
positively associated with years of opioid exposure, suggestive of a 
cumulative process associated with prolonged opioid misuse. The ABS group 
had a significant reduction in white matter in the dorsolateral prefrontal cortex, 
ventricles and posterior cingulate cortex relative to healthy controls. In 
contrast, the MMT participants had thalamic and prefrontal cortex white matter 
reductions. Variation in the compulsivity/impulsivity ratio correlated with 
amygdala and striatal grey matter reductions. A correlation analysis revealed 
that opioid exposure also correlated negatively with globus pallidus grey 
matter. 
 Previous studies have suggested that the need to keep taking drugs to 
avoid a withdrawal syndrome (impulsivity) and the intense drug craving 
(compulsivity) are inseparable cognitive endophenotypes [9]. However we 
believe that our results  are consistent with Holander and Wong’s alternative 
proposal of the compulsive-impulsive diathesis model, with impulsivity and 
compulsivity at the opposite ends of a single dimension [19]. Impaired set-
shifting has been found in the short-term ABS  and H groups but not in the 
MMT group. Such reversal-learning/set-shifting impairments have been linked 
to dysfunction of serotonin in the OFC [33,34] and dysfunction of dopamine in 
the striatum [35]. It might be that methadone treatment helped in rescuing 
behavioural flexibility via normalisation of the OFC serotoninergic tone, which 
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was then impaired after methadone cessation. However due to the cross-
sectional design of the current study we cannot address causal effects.  
Our findings provide compelling evidence that the ABS group were 
impaired on compulsivity measures. We also found a negative correlation 
between compulsivity and impulsivity measures. The variables (a) total errors 
(IED) and pre-ED errors for compulsivity, and (b) risk adjustment and quality 
of decision making for impulsivity, were the relevant variables in the linear 
regression models. These findings suggest that there are differential cognitive 
impairments relative to the different stages of the addiction cycle. We also 
found evidence for abnormal brain structure: ABS and MMT groups exhibited 
white matter reductions relative to the HC group. The ABS group additionally 
had grey matter reduction in dorsolateral prefrontal cortex, ventricles and 
posterior cingulate. Notably the prefrontal cortex is linked to IED set-shifting’s 
impairments in non-human primates [36] and humans [37]. Significant 
decreases in white matter were found in the MMT group in medial prefrontal 
cortex and anterior cingulate cortex. These structures have been implicated in 
the regulation of rewards, emotions and decision-making [1].  The medial 
prefrontal cortex plays a critical role in decision-making, such as conflict 
monitoring [38], error detection [39], and adaptive and emotional 
responses,[40, 41] with the anterior cingulate cortex being activated during 
negative affect and cognitive control [42]. 
The ABS group also exhibited white matter reductions adjacent to the 
insula and subcortical (nucleus accumbens and ventral tegmental area) 
structures with increased EDS errors. Notably, the insula has been implicated 
in craving for  opioid dependence [24].  
Robbins and colleagues proposed that both compulsivity and 
impulsivity are linked to abnormal striatal and prefrontal cortex functioning [9]. 
Consistent with this, we found the compulsivity/impulsivity ratio was 
associated with nucleus accumbens/striatal structural reductions in the ABS 
group and orbitofrontal cortex in the MMT group. Abnormal globus pallidus 
structure is associated with heroin intoxication [43] and is strongly associated 
with motor impairments [44] associated with impulsivity (risk adjustment) and 
methadone dose [8]. Our study found grey matter reductions in globus 
pallidus associated with duration of exposure to opioids. Interestingly both 
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impulsivity and compulsivity measures were correlated with increasing years 
of opioid abuse suggesting a cumulative effect of opioid use. 
In summary, short term opioid abstinence was associated with 
persistent compulsivity related impairments and associated brain structural 
abnormalities. To establish a possible clinical endophenotype of abstinence, a 
longitudinal study is required. 
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